OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Organization: AgeneBio Inc

6 Projects | 2 Researchers | $3,342,291 Invested

2019

AgeneBio Inc

Sharon Rosenzweig-Lipson, PhD

In Vivo Characterization of a GABA-A alpha-5 Positive Allosteric Modulator

  • Funding Amount: $499,704
  • Organization Type: Biotechnology/For Profit
  • Program: Drug Discovery
  • Target: Synaptic Activity and Neurotransmitters
  • Status: Closed

2018

AgeneBio Inc

Michela Gallagher, PhD

2018 Annual Goodes Prize for Excellence in Alzheimer’s Drug Discovery: Imaging Sub-study for the HOPE4MCI Phase 3 Trial

  • Funding Amount: $150,000
  • Organization Type: Biotechnology/For Profit
  • Program: Clinical
  • Target: Synaptic Activity and Neurotransmitters
  • Status: Closed

2016

AgeneBio Inc

Sharon Rosenzweig-Lipson, PhD

Accelerating Manufacture of Clinical Supplies for Initiation of Patient Enrollment in the HOPE4MCI Phase 3 Trial (AgeneBio, AGB101)

  • Funding Amount: $798,087
  • Organization Type: Biotechnology/For Profit
  • Program: Clinical
  • Target: Synaptic Activity and Neurotransmitters
  • Status: Closed

2016

AgeneBio Inc

Sharon Rosenzweig-Lipson, PhD

GABA-A alpha-5 Positive Allosteric Modulators for the treatment of aMCI due to AD.

  • Funding Amount: $750,000
  • Organization Type: Biotechnology/For Profit
  • Program: Drug Discovery
  • Target: Synaptic Activity and Neurotransmitters
  • Status: Closed

2014

AgeneBio Inc

Sharon Rosenzweig-Lipson, PhD

Accelerating a Phase III MCI Clinical Trial with Phase I Evaluation of a Novel Extended-Release Levetiracetam Formulation

  • Funding Amount: $900,000
  • Organization Type: Biotechnology/For Profit
  • Program: Clinical
  • Target: Synaptic Activity and Neurotransmitters
  • Status: Closed

2010

AgeneBio Inc

Michela Gallagher, PhD

Selective GABA a5 ligands for cognitive enhancement in patients with Mild Cognitive Impairment

  • Funding Amount: $244,500
  • Organization Type: Biotechnology/For Profit
  • Program: Drug Discovery
  • Status: Closed